Current oncology最新文献_第9页

Stepping Stones to Sustainability Within Cancer Clinical Trials in Ireland. 踏脚石在爱尔兰癌症临床试验的可持续性。

IF 3.4 4区医学

Current oncology Pub Date : 2025-08-08 DOI: 10.3390/curroncol32080446

Angela Clayton-Lea, Calvin R Flynn, Claire Hopkins, Seamus O'Reilly

{"title":"Stepping Stones to Sustainability Within Cancer Clinical Trials in Ireland.","authors":"Angela Clayton-Lea, Calvin R Flynn, Claire Hopkins, Seamus O'Reilly","doi":"10.3390/curroncol32080446","DOIUrl":"https://doi.org/10.3390/curroncol32080446","url":null,"abstract":"Cancer clinical trials contribute significantly to healthcare-related greenhouse gas emissions, highlighting the need to address sustainability in this area as the climate crisis intensifies. This study provides the first national assessment of sustainability awareness, attitudes, and practices within the Irish cancer clinical trials community. A 21-item cross-sectional survey was distributed to 613 cancer research professionals affiliated with Cancer Trials Ireland, including clinicians, research nurses, trial coordinators, patient advocates and industry staff, yielding a 20.6% response rate. Survey items assessed awareness of sustainability tools, perceived carbon contributors, training received, confidence in implementing green practices, and perceived barriers and enablers to sustainability. Awareness of existing carbon footprint tools was low, with only 21% familiar with the Sustainable Clinical Trials Group guidelines and fewer than 6% aware of the National Institute for Health and Care Research calculator. Despite limited training and low confidence in implementing carbon-reductive measures, 86% of respondents expressed willingness to engage with sustainability initiatives. Trial-related travel, sample kit waste, and trial set-up were perceived as the highest contributors to emissions, though perceptions did not always align with published data. Key barriers included lack of education, institutional support, and regulatory clarity, while financial incentives and training were identified as enablers. Coordinated, system-wide interventions are needed to embed sustainability into cancer clinical trial design, governance, and funding processes.","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 8","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12385077/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144946170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Population-Based Study of Sex Differences in Cardiovascular Disease Mortality Among Adults with Ocular Cancer in the United States, 2000-2021. 2000-2021年美国成人眼癌患者心血管疾病死亡率性别差异基于人群的研究

IF 3.4 4区医学

Current oncology Pub Date : 2025-08-08 DOI: 10.3390/curroncol32080447

Duke Appiah, Abdulkader Almosa, Eli Heath, Noah De La Cruz, Obadeh Shabaneh

{"title":"A Population-Based Study of Sex Differences in Cardiovascular Disease Mortality Among Adults with Ocular Cancer in the United States, 2000-2021.","authors":"Duke Appiah, Abdulkader Almosa, Eli Heath, Noah De La Cruz, Obadeh Shabaneh","doi":"10.3390/curroncol32080447","DOIUrl":"https://doi.org/10.3390/curroncol32080447","url":null,"abstract":"Little is known about the manifestation of cardiovascular diseases (CVD) among individuals with ocular cancer (OC), a population for whom reports on sex-based differences in survival remain inconsistent. We evaluated the occurrence of CVD mortality after the diagnosis of OC in the United States. We used data from 11,460 adults diagnosed with OC from 2000 to 2021 who were ≥18 years and were enrolled in the Surveillance, Epidemiology, and End Results program. We used competing risk models to estimate hazard ratios (HR) and 95% confidence intervals (CI). About 55% of adults were male, with uveal melanoma being the most common OC (72.1%). During a median follow-up of 5.4 years, 4561 deaths occurred, with 15% attributable to CVD. In models adjusted for sociodemographic and clinico-pathophysiological factors, male adults had elevated risk for CVD mortality (HR: 1.54, 95%CI: 1.31-1.81). The sex difference in CVD mortality was more prominent for adults diagnosed with OC before 65 years of age (HR: 2.15; 95%CI: 1.48-3.11). These associations remained largely unchanged in propensity score analysis. In this study of adults with OC, CVD deaths were higher among young and middle-aged males. Implementation of optimal cardiovascular health interventions after diagnosis of OC, especially among men, holds promise in enhancing survival in this population.","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 8","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12384198/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144946046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multidisciplinary Practical Guidance for Implementing Adjuvant CDK4/6 Inhibitors for Patients with HR-Positive, HER2-Negative Early Breast Cancer in Canada. 加拿大hr阳性、her2阴性早期乳腺癌患者使用辅助CDK4/6抑制剂的多学科实用指南

IF 3.4 4区医学

Current oncology Pub Date : 2025-08-07 DOI: 10.3390/curroncol32080444

Katarzyna J Jerzak, Sandeep Sehdev, Jean-François Boileau, Christine Brezden-Masley, Nadia Califaretti, Scott Edwards, Jenn Gordon, Jan-Willem Henning, Nathalie LeVasseur, Cindy Railton

{"title":"Multidisciplinary Practical Guidance for Implementing Adjuvant CDK4/6 Inhibitors for Patients with HR-Positive, HER2-Negative Early Breast Cancer in Canada.","authors":"Katarzyna J Jerzak, Sandeep Sehdev, Jean-François Boileau, Christine Brezden-Masley, Nadia Califaretti, Scott Edwards, Jenn Gordon, Jan-Willem Henning, Nathalie LeVasseur, Cindy Railton","doi":"10.3390/curroncol32080444","DOIUrl":"https://doi.org/10.3390/curroncol32080444","url":null,"abstract":"Cyclin-dependent kinase (CDK)4/6 inhibitors have become a key component of adjuvant treatment for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer who are at high risk of recurrence. The addition of abemaciclib and ribociclib to standard endocrine therapy has demonstrated clinically meaningful improvements in invasive disease-free survival, supported by the monarchE and NATALEE trials, respectively. With expansion of patient eligibility for CDK4/6 inhibitors, multidisciplinary coordination among medical oncologists, surgeons, nurses, pharmacists, and other health care providers is critical to optimizing patient identification, monitoring, and management of adverse events. This expert guidance document provides practical recommendations for implementing adjuvant CDK4/6 inhibitor therapy in routine clinical practice, incorporating insights from multiple specialties and with patient advocacy representation. Key considerations include patient selection based on clinical trial data, treatment duration, dosing schedules, adverse event profiles, monitoring requirements, drug-drug interactions, and patient-specific factors such as tolerability, cost, and quality of life. This guidance aims to support Canadian clinicians in effectively integrating CDK4/6 inhibitors into clinical practice, ensuring optimal patient outcomes through a multidisciplinary and patient-centric approach.","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 8","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12384589/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144946100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New Trends in Thyroid Malignancy: Minimally Invasive Thermal Ablation Percutaneous Techniques for T1 Papillary Thyroid Carcinomas. 甲状腺恶性肿瘤的新趋势：经皮微创热消融技术治疗T1型甲状腺乳头状癌。

IF 3.4 4区医学

Current oncology Pub Date : 2025-08-07 DOI: 10.3390/curroncol32080442

Pierre Yves Marcy

引用次数: 0

Impact of Surgical Margin Control in Index Tumors on Prognosis After Radical Prostatectomy: A Focus on Zonal Origin. 指数肿瘤手术切缘控制对根治性前列腺切除术后预后的影响：聚焦于区域性起源。

IF 3.4 4区医学

Current oncology Pub Date : 2025-08-07 DOI: 10.3390/curroncol32080445

Jun Akatsuka, Yoshihiko Ogata, Kotaro Obayashi, Mami Takadate, Shunsuke Ikuma, Hiroya Hasegawa, Hikaru Mikami, Hayato Takeda, Yuki Endo, Takayuki Takahashi, Kaori Ono, Yuka Toyama, Yoichiro Yamamoto, Go Kimura, Yukihiro Kondo

{"title":"Impact of Surgical Margin Control in Index Tumors on Prognosis After Radical Prostatectomy: A Focus on Zonal Origin.","authors":"Jun Akatsuka, Yoshihiko Ogata, Kotaro Obayashi, Mami Takadate, Shunsuke Ikuma, Hiroya Hasegawa, Hikaru Mikami, Hayato Takeda, Yuki Endo, Takayuki Takahashi, Kaori Ono, Yuka Toyama, Yoichiro Yamamoto, Go Kimura, Yukihiro Kondo","doi":"10.3390/curroncol32080445","DOIUrl":"https://doi.org/10.3390/curroncol32080445","url":null,"abstract":"We investigated the clinical significance of positive surgical margins (PSMs) in index tumors following radical prostatectomy (RP), with particular attention to the tumor's zonal origin. Among 1148 patients with localized prostate cancer who underwent RPs, 973 were included after excluding those who received perioperative therapy or had incomplete data. Index tumors were categorized by zonal origin: transition zone, peripheral zone, or central zone (CZ). Overall, PSMs were observed in 26.4% of index tumors. Although CZ index tumors were relatively uncommon (6.5%), they exhibited the highest PSM rate (42.9%) and showed the most aggressive pathological features. The 5-year biochemical recurrence (BCR)-free survival rate was significantly lower in patients with PSMs in index tumors than in those with negative surgical margins (45.6% vs. 86.8%, p < 0.0001). Notably, patients with PSMs in CZ index tumors had the worst outcomes, with a 5-year BCR-free survival rate of 22.0%. Multivariate analysis identified PSMs in index tumors as an independent predictor of BCR (HR: 3.4; 95% CI: 2.5-4.5), with a similar trend observed in early recurrence. These findings highlight the prognostic significance of PSMs in index tumors during RP, especially in CZ tumors, and emphasize the importance of securing local control in these cases.","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 8","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12385668/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144946140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Review on the Evolving Role of Radiation Therapy in the Treatment of Locally Advanced Rectal Cancer. 放射治疗在局部晚期直肠癌治疗中的作用

IF 3.4 4区医学

Current oncology Pub Date : 2025-08-07 DOI: 10.3390/curroncol32080443

Zeinab Dandash, Tala Mobayed, Sally Temraz, Ali Shamseddine, Samer Doughan, Samer Deeba, Zeina Ayoub, Toufic Eid, Bassem Youssef, Lara Hilal

引用次数: 0

Seronegative Paraneoplastic Opsoclonus-Myoclonus-Ataxia Syndrome Secondary to Low Volume Endocrine-Sensitive Malignancy of Likely Breast Origin. 可能起源于乳腺的低体积内分泌敏感恶性肿瘤继发的血清阴性副肿瘤嗜中性-肌中性-共济失调综合征。

IF 3.4 4区医学

Current oncology Pub Date : 2025-08-06 DOI: 10.3390/curroncol32080440

Geraint Berger, Caitlin Jackson-Tarlton, Daniel Rayson, Alexander Silver, Mark Walsh, Ashley Drohan

{"title":"Seronegative Paraneoplastic Opsoclonus-Myoclonus-Ataxia Syndrome Secondary to Low Volume Endocrine-Sensitive Malignancy of Likely Breast Origin.","authors":"Geraint Berger, Caitlin Jackson-Tarlton, Daniel Rayson, Alexander Silver, Mark Walsh, Ashley Drohan","doi":"10.3390/curroncol32080440","DOIUrl":"https://doi.org/10.3390/curroncol32080440","url":null,"abstract":"A 51-year-old female presented to the emergency department with vertigo, visual disturbances, involuntary rapid repetitive eye movements, incoordination, and imbalance. Physical examination revealed opsoclonus, myoclonus, and bilateral limb and gait ataxia. Initial workup was negative for intracranial abnormalities, and no abnormalities were noted on blood work or cerebrospinal fluid analysis. Tumor markers were within normal limits. As part of her diagnostic workup, a positron emission tomography (PET) scan was performed, which showed a highly FDG-avid solitary 7 mm left axillary lymph node. Ultrasound-guided percutaneous biopsy revealed metastatic poorly differentiated carcinoma. Histopathological examination could not conclusively distinguish between adenocarcinoma and squamous cell carcinoma. She was diagnosed with seronegative opsoclonus-myoclonus ataxia syndrome of paraneoplastic origin from an occult primary malignancy and started on pulsatile corticosteroids and intravenous immunoglobulin (IVIG), with only moderate symptomatic improvement. Given the anatomic location and immunohistochemical staining pattern of the lymph node, the malignancy was considered as being of primary breast origin. A left axillary lymph node dissection was performed, with 1/12 nodes testing positive for poorly differentiated carcinoma. The patient experienced significant improvement in her neurological symptoms 2-3 days following resection of the solitary malignant lymph node, largely regaining her functional independence. She went on to receive adjuvant radiotherapy to the breast and axilla, as well as adjuvant hormonal therapy.","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 8","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12384546/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144946084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Trends in the Utilization of BRCA1 and BRCA2 Testing After the Introduction of a Publicly Funded Genetic Testing Program. 引入公共资助的基因检测项目后，BRCA1和BRCA2检测的使用趋势。

IF 3.4 4区医学

Current oncology Pub Date : 2025-08-06 DOI: 10.3390/curroncol32080439

Fahima Dossa, Nancy N Baxter, Rinku Sutradhar, Tari Little, Lea Velsher, Jordan Lerner-Ellis, Andrea Eisen, Kelly Metcalfe

{"title":"Trends in the Utilization of BRCA1 and BRCA2 Testing After the Introduction of a Publicly Funded Genetic Testing Program.","authors":"Fahima Dossa, Nancy N Baxter, Rinku Sutradhar, Tari Little, Lea Velsher, Jordan Lerner-Ellis, Andrea Eisen, Kelly Metcalfe","doi":"10.3390/curroncol32080439","DOIUrl":"https://doi.org/10.3390/curroncol32080439","url":null,"abstract":"Purpose: To effectively reduce cancer burden, genetic testing programs should identify high-risk individuals prior to cancer development, when risk-reduction strategies can be implemented. We evaluated trends in BRCA1/BRCA2 testing use after implementation of a publicly funded testing program.Methods: We conducted a retrospective, near population-based study of women who underwent BRCA1/BRCA2 testing in Ontario, Canada, (2007-2016) (n = 15,986). Temporal trends were evaluated using linear and Poisson regression.Results: Although annual utilization of testing increased over time (p < 0.001), mean age at testing increased from 49.9 years (SD 13.8) in 2007 to 53.8 years (SD 13.7) in 2016 (p < 0.001). The proportion of women with a cancer history at testing also increased from 53.5% in 2007 to 66.3% in 2015 (p < 0.001); the proportion of women free from breast cancer did not change significantly (49.2% in 2007 versus 45.1% in 2015, p = 0.90). As a proportion of all tested, those with breast cancer tested within 3 months of diagnosis increased over time (0.39% of tests in 2007 versus 13.6% of tests in 2015; p < 0.001).Conclusions: While the institution of a publicly funded genetic testing program was associated with rising utilization, increasing age at testing and decreasing testing of unaffected women suggest limitations in identifying high-risk individuals eligible for risk-reduction.","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 8","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12384781/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144946159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and Safety of Dose-Dense Chemotherapy in Breast Cancer: Real Clinical Data and Literature Review. 剂量密集化疗在乳腺癌中的疗效和安全性：真实临床数据和文献综述。

IF 3.4 4区医学

Current oncology Pub Date : 2025-08-06 DOI: 10.3390/curroncol32080441

Keiko Yanagihara, Masato Yoshida, Tamami Yamakawa, Sena Kato, Miki Tamura, Koji Nagata

{"title":"Efficacy and Safety of Dose-Dense Chemotherapy in Breast Cancer: Real Clinical Data and Literature Review.","authors":"Keiko Yanagihara, Masato Yoshida, Tamami Yamakawa, Sena Kato, Miki Tamura, Koji Nagata","doi":"10.3390/curroncol32080441","DOIUrl":"10.3390/curroncol32080441","url":null,"abstract":"Dose-dense chemotherapy shortens the interval between chemotherapy cycles and has shown improved outcomes in high-risk breast cancer patients. We retrospectively evaluated the efficacy and safety of dose-dense chemotherapy in 80 breast cancer patients treated at our hospital from 2020 to 2024. The regimen included epirubicin and cyclophosphamide followed by paclitaxel or docetaxel, with pegfilgrastim support. The overall treatment completion rate was 82.5%. Of the 80 patients, 55 underwent neoadjuvant chemotherapy, and the pathological complete response rate was significantly higher in triple-negative breast cancer (59.1%) compared to that in luminal-type cancer (9.1%). Common adverse events included anemia, liver dysfunction, myalgia, and peripheral neuropathy. Febrile neutropenia occurred in 8.8% of patients, with some cases linked to pegfilgrastim body pod use, particularly in individuals with low subcutaneous fat. Notably, two patients developed pneumocystis pneumonia, potentially associated with steroid administration. Despite these toxicities, most were manageable and resolved after treatment. Our findings support the efficacy of dose-dense chemotherapy, particularly in triple-negative breast cancer, while highlighting the importance of individualized supportive care and vigilance regarding hematologic and infectious complications.","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 8","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12384713/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144946011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Biological Aging and Chemotoxicity in Patients with Colorectal Cancer: A Secondary Data Analysis Using EHR Data. 结直肠癌患者的生物老化和化学毒性：使用电子病历数据的二次数据分析。

IF 3.4 4区医学

Current oncology Pub Date : 2025-08-05 DOI: 10.3390/curroncol32080438

Claire J Han, Ashley E Rosko, Jesse J Plascak, Alai Tan, Anne M Noonan, Christin E Burd

{"title":"Biological Aging and Chemotoxicity in Patients with Colorectal Cancer: A Secondary Data Analysis Using EHR Data.","authors":"Claire J Han, Ashley E Rosko, Jesse J Plascak, Alai Tan, Anne M Noonan, Christin E Burd","doi":"10.3390/curroncol32080438","DOIUrl":"https://doi.org/10.3390/curroncol32080438","url":null,"abstract":"Background: Biological aging influences cancer outcomes, but its changes during chemotherapy and impact on chemotoxicity in colorectal cancer (CRC) remain underinvestigated. We examined (1) trajectories of biological aging (using Levine Phenotypic Age) during six months of chemotherapy, (2) sociodemographic and clinical risk factors for biological aging, and (3) links between biological aging and chemotoxicity. Methods: Using data from electronic health records (2013-2019) from 1129 adult CRC patients, we computed biological aging (raw Levine Phenotypic Age and its age acceleration [Levine Phenotypic Age-chronological age]) from routine blood tests (e.g., complete blood counts, hepatorenal/inflammatory markers). Chemotoxicity was identified primarily via International Classification of Diseases (ICD-9 and -10) codes. Results: Chemotherapy accelerated biological aging over time. Biological aging at baseline and changes over time predicted chemotoxicity. However, changes in biological aging over time showed stronger associations than baseline biological aging. Advanced cancer stages, higher comorbidity burden, and socioeconomic disadvantage (especially area-level deprivation) were associated with accelerated biological aging at baseline and over time. Biological aging occurred across both young and older adults. Conclusions: Levine Phenotypic Age, computed from routine blood tests in EHRs, offers a feasible clinical tool for aging-related chemotoxicity risk stratification. Validation in diverse cohorts and the development of predictive models are needed.","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 8","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12384179/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144946034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0